Bailong Chuangyuan(SH:605016) Xin Lang Cai Jing·2025-07-31 08:24Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth in its health sweetener products, particularly allulose, which is beneficial for obesity and diabetes patients, and is also benefiting from the depreciation of the RMB and its status as a "specialized, refined, distinctive, and innovative" enterprise [2][4]. Company Overview - Shandong Bailong Chuangyuan was established on December 30, 2005, and went public on April 21, 2021. The company focuses on the research, production, and sales of prebiotic products, dietary fiber products, and health sweeteners [8]. - The main revenue composition includes dietary fiber series (54.15%), prebiotic series (28.00%), health sweeteners (13.57%), and others (3.91%) [8]. Financial Performance - For the first quarter of 2025, the company achieved revenue of 313 million yuan, a year-on-year increase of 24.27%, and a net profit attributable to shareholders of 81.42 million yuan, up 52.06% year-on-year [8]. - The company has distributed a total of 162 million yuan in dividends since its A-share listing, with 151 million yuan distributed in the last three years [9]. Shareholding and Market Activity - As of July 20, 2023, the number of shareholders is 11,800, a decrease of 5.12% from the previous period, with an average of 35,642 circulating shares per person, an increase of 5.40% [8]. - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank [3]. Market Position and Industry Context - The company is classified under the basic chemical industry, specifically in food and feed additives, and is part of several concept sectors including sugar substitutes and value growth [8]. - The company has a significant overseas revenue share of 60.62%, benefiting from the depreciation of the RMB [4].